Antheia’s 2024 in Review: A Year Of Collaboration
As we reflect on 2024, it’s been a significant year of collaboration, with every Antheia employee and partner helping us move closer toward our mission of transforming pharmaceutical supply chains and ending essential medicine shortages. No one person, company, or organization can solve a daunting global problem like drug shortages alone, but we have made […]
Antheia Lands $12M with Second BioMaP Deal to Reshape U.S. Pharma
The company was awarded for its ability to outperform conventional manufacturing methods for critical pharmaceutical ingredients and rapidly reach a commercial scale in the U.S.
Antheia Secures Second Project Agreement with the BioMaP-Consortium Valued at up to $12M
Company awarded for its ability to outperform conventional manufacturing methods for critical pharmaceutical ingredients and rapidly reach commercial scale in the U.S.
InnovationRx: Venture Investments Into Biopharma And Medtech Reverse 2-Year Slide
Antheia, which is using fermentation to manufacture drug ingredients that are normally produced agriculturally, announced its first commercial delivery this week.
Antheia Fulfills First Commercial Delivery of Thebaine
Antheia, a pharmaceutical ingredient manufacturer, has delivered its first commercial order of thebaine to a leading pharmaceutical customer.
Antheia’s First Commercial Thebaine Delivery Sets New Standard in Pharmaceutical Biomanufacturing
This first commercial-scale thebaine delivery redefines essential medicine supply chains, supporting biomanufacturing’s future in pharma.
Brewing Medicines with Synthetic Biology: Antheia’s Christina Smolke on Ending Drug Shortages
In this episode of the Grow Everything Biotech Podcast, Karl and Erum welcome Christina Smolke, CEO of Antheia and Professor at Stanford University, to discuss the rapid changes happening in biotech, particularly focusing on the biohacking community and decentralized science (DCI).
Synthetic Biology at Scale: Less Disruption, More Cohesion
For synthetic biology companies, scaling up means reaching out—working with government bodies, identifying partners, and securing manufacturing capacity
Antheia Secures $17 Million to Boost U.S. Production of Critical Pharmaceutical Ingredients
Antheia, a pioneering pharmaceutical ingredient manufacturer, has announced a significant $17 million funding boost aimed at transforming the supply chains of essential medicines.
Antheia Announces $17 Million in Funding for Domestic Pharmaceutical Ingredient Production
Antheia announced that it has received $17 million in funding to be used for projects focused on building domestic pharmaceutical production sites.